Dr Filozof is Vice President and Therapeutic Area Head in Obesity, MASH and Liver indications in Fortrea. Her expertise is broad and ranges from clinical trials and drug development to Global medical affairs, market launches, all on a global scale and across multiple therapy areas, including Obesity, Diabetes (T2DM), dyslipidemias, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and multiple hepatology indications and rare diseases.
Dr Filozof lead development programs in T2DM, obesity, severe high triglycerides and MASLD. Her interest in obesity and related metabolic conditions triggered her interest in MASLD/ MASH (metabolic associated steatohepatitis) 13 years ago. During these years she has been very active with the scientific community in this indication and published 6 review articles about drug development in this indication in peer review journals. During the first 20 years of her career, Dr Filozof worked in academia, being Vice President of the Argentinean Society of Obesity, Editor –in-chief of the Argentinean Obesity Journal, Professor and Director of the Post Graduate Course in Obesity at John F Kennedy University, Board member of the international journal: Obesity Reviews for several years, member of the World Obesity Federation award committee for 2 consecutive periods and member of the first WHO Task Force in Obesity. She completed her PhD in energy expenditure, fat oxidation, body composition and cytokines in post obesity.
Dr Filozof joined Fortrea (previously Covance/Labcorp) 10 years ago and has been consulting with several sponsor with strategic study design, helping them to generate high quality data in the most efficient way. She also brings experience in innovative study design and has chaired the multi-functional innovative study designs working group at Fortrea for the last 3 years.
